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Abstract 
Reactivation of varicella zoster virus (VZV) can manifest with facial palsy diagnosed as 
Ramsay Hunt Syndrome (RHS) or Ramsay Hunt Syndrome zoster sine herpete (RHS-ZSH). These 
syndromes are associated with poor prognosis despite treatment with antivirals and corticosteroids. 
Concentrations of biomarkers such as neurofilament protein (NFL), S-100ß protein and glial 
fibrillary acidic protein (GFAp) have previously been measured in cerebrospinal fluid (CSF) to 
assess neuronal damage and glial pathology. 
We employed immunochemical methods to measure concentrations of NFL, S-100ß protein and 
GFAp in CSF from patients with RHS (n=15) and RHS-ZSH (n=13) diagnosed by detection of 
VZV DNA in the CSF by quantitative PCR, and compared with a control group (n=52). The 
biomarker concentrations were correlated to CSF viral load and outcome measured by House-
Brackmann score. 
NFL and GFAp concentrations were increased compared with controls (p < 0.01 and p < 0.05), 
while S-100ß levels were decreased. This pattern was more pronounced in patients with RHS 
compared to the patients with RHS-ZSH (NS and p < 0.05). The amount of viral DNA in CSF 
correlated with increased GFAp (p < 0.01) and NFL (p < 0.01). No correlations were found between 
biomarker concentrations and patient outcome. 
Patients with facial palsy caused by VZV had biochemical signs of neuronal damage and 
astrogliosis. High amounts of viral DNA may be associated with the degree of damage on neuronal 
and astroglial cells. Prospective studies are warranted to elucidate the association of elevated 
biomarkers in the CSF and outcome assessed by more sensitive tests.  
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Introduction 
Reactivation of varicella zoster virus (VZV) can manifest as a variety of central nervous system 
(CNS) syndromes with a risk of serious and even fatal complications (Gilden, 2004). Facial nerve 
palsy caused by reactivation of VZV from the geniculate ganglion (Wackym, 1997), is commonly 
accompanied by a typical vesicular rash in the ipsilateral ear, and is named Ramsay Hunt syndrome  
(RHS). The blisters may also be localised in the hard palate and/or on the anterior two thirds of the 
tongue. Associated symptoms are vestibulocochlear dysfunctions such as vertigo, hearing loss, and 
tinnitus (Sweeney & Gilden, 2001). However, reactivation of VZV with neurological symptoms 
may also occur without the presence of rash, zoster sine herpete (ZSH). Improved diagnostic 
methods including PCR has facilitated the differentiation between Ramsay Hunt syndrome zoster 
sine herpete (RHS-ZSH) and other causes of facial nerve palsy such as Bell’s palsy (Gilden et al., 
1994). Detection of VZV DNA by PCR and/or antibody-detection in the cerebrospinal fluid (CSF) 
are first-line methods for diagnosis (Gilden et al., 2010).  
The prognosis of RHS has been shown to be worse than in Bell’s palsy. Without treatment only 
one in ten patients with total facial paralysis recover, and in patients with subtotal facial paralysis 
approximately two thirds recover (Devriese & Moesker, 1988). Antiviral treatment is available with 
aciclovir, and is recommended in RHS in conjunction with corticosteroids (Gnann, 2002). Overall, 
despite treatment, only three in five patients recover, and with multiple cranial neuropathy, only 
approximately a third, as compared to more than four in five patients with Bell’s palsy (Shim et al., 
2011; Ryu et al., 2012).  
The potential association between neurological damage, severity of symptoms in RHS and 
outcome is poorly investigated, and the neuropathology involved remains unclear. Concentrations 
of biochemical markers in the CSF can be measured to assess neuronal damage, glial pathology and 
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inflammation. Neurofilament light protein (NFL) is a component of the axonal neurofilament core 
and a marker of neuron pathology (Rosengren et al., 1996; Norgren et al., 2003). S-100ß protein 
and glial fibrillary acidic protein (GFAp) both reflect astroglial cell leakage (Rothermundt et al., 
2003; Petzold, 2015). CSF biomarkers have been used to estimate severity of neuronal damage and 
prognosis in various CNS diseases (Aurell et al., 1991; Nylen et al., 2002; Teunissen et al., 2009), 
including viral infections such as herpes simplex encephalitis (HSE) and tick-borne encephalitis 
(TBE) (Studahl et al., 2000). Only one recent study has been made on VZV infections of the CNS, 
where the elevated levels of NFL and GFAp in the CSF suggested neuronal damage and astrogliosis 
(Grahn et al., 2013). In that study, only 3 patients with facial nerve palsy were included. CSF viral 
load as a biomarker, measured through quantitative real-time PCR, has hitherto been investigated in 
two studies on VZV CNS syndromes (Aberle et al., 2005; Persson et al., 2009). However, these 
studies only included a total of 20 patients with cranial nerve palsy and they were not specifically 
investigated. 
Our aim was to study the CSF levels and patterns of the biochemical markers NFL, GFAp, S-
100ß as well as viral load in patients with facial nerve palsy caused by VZV compared to controls, 
and relate the results to clinical severity and outcome. 
Materials and methods 
Patients  
Patients were retrospectively identified through CSF samples sent to the Virological Laboratory 
of Sahlgrenska University Hospital during 2002-2013 with detectable VZV DNA by quantitative 
in-house PCR. Patients with facial nerve palsy were identified through their medical records. 
Patients with other coexisting CNS diseases were excluded. 
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Additional information such as demographics, CSF sampling in relation to neurological 
symptoms, antiviral and/or corticosteroid treatment, laboratory workups and associated symptoms 
such as blisters, vertigo, hearing loss and pain at presentation and at follow-up were obtained. 
The Medical Ethics Committee at Gothenburg University approved the study and informed 
consent was obtained from patients prior to their inclusion in the study.  
Twenty-eight patients with VZV DNA in CSF were included (14 female and 14 male; median 
age 60 years, range 17–93). Patient characteristics and clinical data are shown in Table 1. Blisters 
were identified in 15 patients, fulfilling the strict definition of RHS, leaving 13 patients with RHS-
ZSH. Blisters presented at a median of 0 days (concurrent with onset of neurological symptoms) 
(range -5—11). For analytical purposes all patients included were considered one group regardless 
of blisters unless otherwise specified. Associated symptoms were prevalent, consisting in 
localized pain or headache (n = 28). Many patients had signs of multiplex mononeuritis, such 
as vestibular neuritis and vertigo (n = 17), auditory nerve involvement and hearing loss (n = 
17) 10th nerve dysfunction and dysphagia (n = 2), abducens paresis and diplopia (n = 1), and 
possibly brachial plexus involvement with upper limb paresis (n = 2).  Additionally, ten 
patients presented with a temperature above 38°C and two elderly patients presented with 
confusion but otherwise not fulfilling previously presented criteria of encephalitis (Persson et 
al., 2009). Magnetic resonance imaging (MRI) had been performed in 10 patients and in two of 
them an inflamed facial nerve was indicated. Recent signs of ischemia were not seen in any of the 
radiological examinations. 
Treatment with aciclovir was given to 27/28 patients, and was administrated intravenously (n = 
11), intravenously with oral aciclovir or valaciklovir as follow-up (n = 10), or as oral treatment 
exclusively (n = 5). One patient was given aciclovir according to medical records without 
specification of treatment regimen. Aciclovir treatment was initiated concurrent with or after 
lumbar puncture in 19/27 treated patients (median 0; range -3—8), and treatment was given with a 
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median duration of 10.5 days (range 7—26.5). The patient with the longest treatment duration was 
rehospitalized due to severe vertigo and restarted on intravenous treatment during her oral follow-
up. Adjuvant therapy with corticosteroids was given in 17 patients. 
Since the timing of lumbar puncture is considered relevant in regard to the biomarkers measured 
(Rosengren et al., 1996; Studahl et al., 2000), patients where further subgrouped into two groups: 
CSF sampling within 7 days of onset of neurological symptoms (n = 22) or from day 8-15 (n = 5). 
Patients were also subgrouped based on whether treatment was initiated before or after CSF 
sampling, and whether they presented with blisters or not. Analyses were performed both on 
subgroups and all included patients as presented below. 
Control subjects  
Non-infectious subjects with headache or psychoneurotic symptoms undergoing lumbar 
puncture were used as controls. Exclusion criteria were concomitant CNS disease or CNS disease 
identified within one year after sampling, elevated lymphocytes or protein levels in the CSF, 
increased C-reactive protein concentrations in blood, or pathological findings at neurological 
examination. The control subjects were age-matched to the patients. 52 control patients were 
included (30 female and 22 male; median age 60 years, range 16–87).  
CSF samples and analyses  
Patient CSF samples had been analysed for VZV DNA with quantitative in-house PCR 
previously described (Persson et al., 2009) as part of diagnostic procedure of symptoms. In the 
original publication referred to (Persson et al., 2009), the probe sequence was incorrectly described 
and the correct probe should be VZVgB_P CGCGGTCCCAAGTCCCTGGA (Persson et al.). 
Patient CSF samples were stored at -70 °C or -20 °C, and CSF samples from control subjects were 
stored at -70 °C as part of a biobank.  
In this study, all CSF samples were analysed on one occasion using one batch of reagents for 
the biomarkers GFAp, NFL and S-100β by board-certified laboratory technicians according to 
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procedures accredited by the Swedish Board of Accreditation and Conformity Assessment 
(SWEDAC). GFAp concentrations were measured using a previously described in house ELISA 
(Rosengren et al., 1994). NFL concentrations were measured using a commercially available 
sandwich ELISA (Uman Diagnostics, Umeå, Sweden) (Norgren et al., 2003). CSF concentrations 
of S-100β were measured using the Modular system and the S100β reagent kit (Roche Diagnostics, 
Basel, Switzerland). Intra-assay coefficients of variation were ≤ 10%. 
Severity and outcome measures 
In an effort to determine disease severity, extent of facial nerve palsy was retrospectively graded 
using the House-Brackmann facial nerve grading system, a scale from 1 to 6 where 1 is normal 
function and 6 is total lack of movement in corresponding facial muscles (House & Brackmann, 
1985). The highest score served as baseline, and score at the latest follow-up within three months 
was used as outcome when applicable. A House-Brackmann score of 1-2 was considered good 
outcome and 3-6 poor outcomes. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, 
USA). Non-parametric statistical methods were used: Mann-Whitney U test for group comparisons 
and Spearman’s rank test for correlations. P values of < 0.05 were considered significant. 
Results 
Biomarkers 
NFL 
NFL concentrations in CSF were increased in patients with VZV facial palsy (n = 27) (median 
911 ng/l; IQR 484–1620) when compared to the control group (521 ng/l; 337–767) (p = 0,008) (Fig. 
1a). Moreover, the NFL concentrations were significantly increased in patients with blisters, and 
thus RHS, compared to the control group (n = 14) (median 929 ng/l; IQR 512–1668) (p = 0.0046), 
 10
but patients with RHS-ZSH did not have an increase in NFL concentrations (n = 13) (median 508 
ng/l; IQR 395–1685). The difference in NFL concentrations in patients with RHS compared to 
RHS-ZSH was not statistically significant (p = 0.4583). In further subgroup analysis, there was a 
tendency towards increasing NFL concentrations in samples drawn after 7 days after onset of 
neurological symptoms compared to patients with samples within 7 days (748 ng/l; 225–2824 and 
1620 ng/l; 327–7032 respectively) (p = 0.1465) (Fig. 1b). In one patient, NFL could not be analysed 
due to low sample volume. 
GFAp 
A modest increase in GFAp concentrations was shown when all patients (n = 28) (877 ng/l; 
617–1650) were compared to controls (698 ng/l; 420–1082) (p = 0.0403) (Fig. 2). When 
subgrouping and compared to controls, the increase was significant in patients with RHS (n = 15) 
(975 ng/l; 648–3888) (p = 0.0028), but not in patients with RHS-ZSH (n = 13) (747 ng/l; 388–
1033)  (p = 0.9001). When compared, RHS had higher concentrations of GFAp compared to RHS-
ZSH (p = 0.0278). 
S-100β 
Concentrations of S-100β were decreased in CSF from patients (n = 22) (0.22 ng/ml; 0.15–0.27) 
when compared to controls (0.37 ng/ml; 0.27–0.44) (p = 0.0002), but no further differences were 
found after subgrouping. In six patients, low sample volume did not allow for analysis of S-100β. 
Viral load  
VZV DNA concentrations in the CSF of all patients (median 4,683 VZV DNA copies/ml; range 
50–1,148,154) correlated with the concentrations of NFL (Spearman r = 0.51; p < 0.01), GFAp 
(Spearman r = 0.54; p < 0.01) and S-100β (Spearman r = 0.59; p < 0.01) as shown in Fig. 3. There 
was no statistically significant difference in viral load between RHS (median 2239 copies/ml; IQR 
479-57544 and RHS-ZSH (median 5000 copies/ml; IQR 231-33995) (p = 0.6175). Diminishing 
viral loads over time could not be shown in this material, but a non-significant tendency for lower 
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viral load was seen between treatment started before (median 794 copies/ml; IQR 79-25861) and 
after (12359; 1546-52944) (p = 0.072) CSF sampling.  
Biomarkers and symptoms, severity and outcome 
No correlations could be shown between biomarkers, including viral load, and severity of 
symptoms such as facial palsy measured by House Brackmann score, pain, vertigo or hearing 
impairment at peak values or latest follow-up within three months of CSF sampling. When patients 
were subgrouped based on good vs. poor outcome, no significant differences in biomarker 
concentrations could be shown. 
Discussion 
In this first study on biomarkers in RHS and RHS-ZSH, we have identified a pattern of 
increased NFL, increased GFAp and decreased S-100β in CSF, interpreted as signs of neuronal 
damage and astrogliosis (Grahn et al., 2013). The increase in NFL reflects axonal damage, while 
the increase in GFAp in combination with a decreased concentration of S-100β is consistent with 
results in previous studies on neuroborreliosis (Dotevall et al., 1999) and TBE (Studahl et al., 
2000), suggesting astrogliosis rather than damage to the astroglial cell membrane. In addition, these 
results are in line with a recent study on CNS biomarkers of various VZV CNS manifestations. In 
that study, increased CSF concentrations of NFL and GFAp were most pronounced in patients with 
encephalitis, but no increase in biomarker concentrations was shown in patients with peripheral 
nerve symptoms, and only three of the patients included had facial palsy. In our study, the 
biomarker elevations were modest but significant, and possibly reflecting the pathological process 
being more localized as compared to encephalitis, but nonetheless indicative of neuronal damage 
and astrogliosis.  
The neuropathogenesis in RHS is largely unknown. Hunt originally theorized that the 
inflammation was localized to the geniculate ganglion, and that the close proximity of the 
geniculate ganglion to the vestibulocochlear nerve within the bony facial canal was associated with 
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development of the vestibulocochlear symptoms. Increasing amounts of evidence contradict this 
theory. Histopathological findings are scarce, and show variability. In other clinical variants of 
herpes zoster, autopsy findings include both necrosis of the dorsal root ganglia in the spinal cord, 
when infection occurred close to death and, fibrotic dorsal root ganglia in patients with infection 
months to years before (Head et al., 1997). In contrast, necrosis of the geniculate ganglion has not 
been found in RHS patients post mortem. Instead, the few post mortem studies performed have 
shown various findings including none to mild inflammation of the geniculate ganglion, 
perivascular inflammation, demyelination and axonal loss along the facial nerve (Denny-Brown et 
al., 1944; Guldberg-Moller et al., 1959; Blackley et al., 1967; Aleksic et al., 1973). In addition, 
MRI examinations have revealed abnormalities localized not only to the inner ear and 
vestibulocochlear nerve, but also to the facial nerve (Brandle et al., 1996; Chung et al., 2015). The 
intratemporal facial nerve including the geniculate ganglion seems to swell in the acute phase of 
RHS, which has been observed during subtotal decompression surgery (Honda et al., 2002). 
Moreover, presence of VZV DNA has been found in the facial nerve sheath and middle ear mucosa 
as well as vesicles and CSF (Murakami et al., 1998). Taken together, evidence supports 
polyneuropathy with viral spread throughout the affected nerves, which may possibly lead to further 
damage on neurons and astroglial cells as opposed to a localized geniculate ganglionitis.  
The increased CSF concentrations of GFAp in patients with blisters, and thus RHS, compared to 
patients with RHS-ZSH could indicate a difference in the magnitude of inflammatory response, or 
even a difference in the pathogenesis, taken into consideration that it has been previously shown 
that patients with typical RHS have a lower recovery rate compared to patients with RHS-ZSH (Lee 
et al., 2012). In addition, NFL concentrations were significantly elevated in patients with RHS 
compared to controls, but not in patients with RHS-ZSH. Although lacking a statistically significant 
difference in NFL concentrations between the groups with and without blisters, neuronal damage 
was only shown in the group with blisters, raising further questions on the neuropathogenesis in 
RHS and RHS-ZSH respectively.  
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Vasculopathy has been suggested in pathogenesis of other VZV CNS manifestations such as 
encephalitis (Gilden, 2002; Gilden et al., 2009), and multifocal vasculopathy following RHS has 
been described in one HIV patient (Ortiz et al., 2008). Transaxonal spread of VZV to vasa vasorum 
of cranial nerves may produce infarction, leading to cranial nerve polyneuritis (Sweeney & Gilden, 
2001). Reactive astrogliosis has previously been described in ischemic events (Clark et al., 1993; 
Pekny & Nilsson, 2005), and as the pattern of biomarkers in our study indicates astrogliosis, we 
cannot exclude vasculopathy as a possible neuropathological pathway also in patients with facial 
palsy caused by VZV. In our study there was no evidence of patients suffering from infarction. 
However, only 10 out of 28 patients had an MRI performed. 
CSF viral load correlated with NFL and GFAp concentrations, indicating that CSF viral load 
may be used to assess the level of neuronal damage in patients within a well-defined group such as 
facial nerve paralysis caused by VZV. On the other hand, we did not find a significant correlation 
between increased concentrations of NFL, GFAp or CSF viral load and severity of initial symptoms 
or outcome. Additionally, no differences in concentrations of biomarkers were seen between the 
patients when they were subgrouped into poor versus good outcomes. In our previous study on 
biomarkers and VZV infections in the CNS, NFL and GFAp concentrations were higher in patients 
with more severe CNS manifestations (Grahn et al., 2013), and in another study, viral load in CSF 
was shown to correlate with clinical severity (Aberle et al., 2005). However, several limitations of 
the present study may have prevented us from replicating such results. Firstly, variation in timing of 
CSF samplings in relation to symptoms is likely one important factor. In addition, increasing NFL 
concentrations during the course of the disease has previously been shown in CNS infections (17) 
and this phenomenon was also indicated in our study. Secondly, the relatively small size of our 
study in combination with modest elevation of biomarkers impedes statistical significance. Thirdly, 
the insensitivity and variability measuring symptoms retrospectively through assessment of medical 
journals is problematic. The House-Brackmann facial nerve grading scale has been retrospectively 
used before (Leong & Tristram, 2013), but has obvious limitations when used this way. A 
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prospective study including more sensitive methods such as Facial Nerve Grading System 2.0 
(Vrabec et al., 2009), audiometry and caloric testing, and sensitive neuroradiological examinations 
in combination with biomarker sampling would probably add more information. 
As mentioned, antiviral treatment against VZV is available with aciclovir. The combination of 
aciclovir and corticosteroids is considered preferable in Ramsay Hunt syndrome (de Ru & van 
Benthem, 2011) although two Cochrane reviews reported insufficient evidence through lack of 
randomized trials (Uscategui et al., 2008a; b). Early treatment seems to be of significance 
(Murakami et al., 1997; Kinishi et al., 2001), with reported complete recovery as high as 90% 
(Kinishi et al., 2001). Our results, indicating neuronal destruction and astrogliosis already at onset 
of symptoms, emphasize the importance of both early diagnostics and initiation of treatment in 
patients with RHS.  
In conclusion, this study demonstrates that patients with acute peripheral facial palsy caused by 
VZV have increased CSF concentrations of NFL and GFAp in combination with a decrease in S-
100β compared to a control group, indicating neuronal damage and astrogliosis. The amount of 
viral DNA in CSF correlated with increased biomarkers and may be associated with the degree of 
damage on neurons and astroglial cells. Further studies are needed to address the relevance of 
vasculopathy, and correlations on biomarkers and outcome should be studied prospectively using 
more sensitive outcome measures in conjunction with sensitive neuroradiological examinations. 
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